Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/76837
Title:
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
Authors:
Jayson, Gordon C ( 0000-0002-8515-8944 ) ; Mulatero, Clive; Ranson, Malcolm R; Zweit, Jamal; Jackson, Alan; Broughton, Lynn; Wagstaff, John; Hakansson, Leif; Groenewegen, Gerard; Lawrance, Jeremy A L; Tang, Meina; Wauk, Linda; Levitt, Dan; Marreaud, Sandrine; Lehmann, Frederic F; Herold, Manfred; Zwierzina, Heinz
Abstract:
We assessed the tolerability, safety, pharmacokinetics and dose-limiting toxicity (DLT) of the recombinant humanized IgG4 anti-vascular endothelial growth factor (VEGF) monoclonal antibody, HuMV833, in patients with advanced cancer. Cohorts of patients with progressive solid tumours received escalating doses of HuMV833 as a 1-h intravenous (I.V.) infusion on days 1, 15, 22, and 29. Twenty patients (median Eastern Cooperative Oncology Group (ECOG) score 1) were accrued. HuMV833 infusions were well tolerated and there were no grade III or IV toxicities definitely related to the antibody. Grade I or II toxicities probably related to the antibody included fatigue, dyspnoea and rash. There were two episodes of asymptomatic hypocalcaemia, one at grade III and one grade IV, which were recorded in early follow-up. There were eight grade I episodes of asymptomatic elevation of activated partial thromboplastin time (APTT) and two grade III events; one in a patient receiving 1 mg/kg and the other receiving extended doses of 10 mg/kg. Pharmacokinetic analysis revealed a non-linear kinetic and an elimination half-life of between 8.2 (0.3 mg/kg) and 18.7 (10 mg/kg) days. One patient with ovarian cancer experienced a partial response (PR) of 9 months duration and eight had disease stabilisation (SD) including one patient with colorectal carcinoma whose disease was stable for 14 months. In 13 of the 14 samples taken from 12 patients, the plasma concentration of hepatocyte growth factor (HGF) was reduced 24 h after drug administration. HuMV833 is safe and lacked DLT at doses up to 10 mg/kg on this schedule. Multiple doses were well tolerated, despite occasional asymptomatic elevations in APTT. By combining pharmacokinetic, pharmacodynamic and toxicity data, we can identify doses of 1 and 3mg/kg for further investigation. HuMV833 appears to possess some clinical activity.
Affiliation:
Department of Medical Oncology, Cancer Research UK, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK. gordon.jayson@christie-tr.nwest.nhs.uk
Citation:
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. 2005, 41 (4):555-63 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
Mar-2005
URI:
http://hdl.handle.net/10541/76837
DOI:
10.1016/j.ejca.2004.11.021
PubMed ID:
15737560
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorJayson, Gordon C-
dc.contributor.authorMulatero, Clive-
dc.contributor.authorRanson, Malcolm R-
dc.contributor.authorZweit, Jamal-
dc.contributor.authorJackson, Alan-
dc.contributor.authorBroughton, Lynn-
dc.contributor.authorWagstaff, John-
dc.contributor.authorHakansson, Leif-
dc.contributor.authorGroenewegen, Gerard-
dc.contributor.authorLawrance, Jeremy A L-
dc.contributor.authorTang, Meina-
dc.contributor.authorWauk, Linda-
dc.contributor.authorLevitt, Dan-
dc.contributor.authorMarreaud, Sandrine-
dc.contributor.authorLehmann, Frederic F-
dc.contributor.authorHerold, Manfred-
dc.contributor.authorZwierzina, Heinz-
dc.date.accessioned2009-08-10T17:13:11Z-
dc.date.available2009-08-10T17:13:11Z-
dc.date.issued2005-03-
dc.identifier.citationPhase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. 2005, 41 (4):555-63 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid15737560-
dc.identifier.doi10.1016/j.ejca.2004.11.021-
dc.identifier.urihttp://hdl.handle.net/10541/76837-
dc.description.abstractWe assessed the tolerability, safety, pharmacokinetics and dose-limiting toxicity (DLT) of the recombinant humanized IgG4 anti-vascular endothelial growth factor (VEGF) monoclonal antibody, HuMV833, in patients with advanced cancer. Cohorts of patients with progressive solid tumours received escalating doses of HuMV833 as a 1-h intravenous (I.V.) infusion on days 1, 15, 22, and 29. Twenty patients (median Eastern Cooperative Oncology Group (ECOG) score 1) were accrued. HuMV833 infusions were well tolerated and there were no grade III or IV toxicities definitely related to the antibody. Grade I or II toxicities probably related to the antibody included fatigue, dyspnoea and rash. There were two episodes of asymptomatic hypocalcaemia, one at grade III and one grade IV, which were recorded in early follow-up. There were eight grade I episodes of asymptomatic elevation of activated partial thromboplastin time (APTT) and two grade III events; one in a patient receiving 1 mg/kg and the other receiving extended doses of 10 mg/kg. Pharmacokinetic analysis revealed a non-linear kinetic and an elimination half-life of between 8.2 (0.3 mg/kg) and 18.7 (10 mg/kg) days. One patient with ovarian cancer experienced a partial response (PR) of 9 months duration and eight had disease stabilisation (SD) including one patient with colorectal carcinoma whose disease was stable for 14 months. In 13 of the 14 samples taken from 12 patients, the plasma concentration of hepatocyte growth factor (HGF) was reduced 24 h after drug administration. HuMV833 is safe and lacked DLT at doses up to 10 mg/kg on this schedule. Multiple doses were well tolerated, despite occasional asymptomatic elevations in APTT. By combining pharmacokinetic, pharmacodynamic and toxicity data, we can identify doses of 1 and 3mg/kg for further investigation. HuMV833 appears to possess some clinical activity.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms-
dc.subject.meshRecombinant Proteins-
dc.subject.meshTreatment Outcome-
dc.titlePhase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Cancer Research UK, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK. gordon.jayson@christie-tr.nwest.nhs.uken
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.